Allan Wailoo

Publications and Insights

• Insight: The Trump Administration’s US Drug Pricing Proposal – What will happen next?
• Insight: Bold politics – what about the economics?: An overview of President Trump’s ‘Most Favoured Nation’ Executive Order
• Publication: Employer Costs from Respiratory Infections
• Insight: Latest estimates show that 20 people a day die in unrelieved pain across the UK at the end of their lives
• Publication: The Dynamics of Drug Shortages
• Publication: Innovation for Health System Efficiency and Improvement
• Publication: Reimagining Prevention for a Healthier, More Prosperous Society
• Bulletin: Health economists for a sustainable future
• Bulletin: Is the NHS too brittle for change?
• Publication: Delivering the Triple Win: A Value-Based Approach to Pricing
• Bulletin: Building a resilient and sustainable healthcare in 2023
• Insight: Improving the Measurement of Valued Output in Primary Care in England
• Publication: Supporting the Era of Green Pharmaceuticals in the UK
• Publication: Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers
• Publication: Payment Models for Multi-Indication Therapies
• Publication: The Lower Drug Costs Now Act and Pharmaceutical Innovation
• Publication: Opportunities to Increase Efficiency in Healthcare
• Publication: Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-Based Policies
• New: Cheap and Dirty: The Effect of Contracting Out Cleaning on Efficiency and Effectiveness
• Publication: Unrelieved Pain in Palliative Care in England
• Publication: Valuing Health at the End of Life: A Stated Preference Discrete Choice Experiment
• Publication: Valuing Health at the End of Life: An Exploratory Preference Elicitation Study